Abstract:Cyclin D1 overexpression may contribute to development of various cancers, including breast cancer, and thus may serve as a key cancer diagnostic marker and therapeutic target. In our previous study, we generated a cyclin D1-specific single-chain variable fragment antibody (ADκ) from a human semi-synthetic single-chain variable fragment library. ADκ specifically interacted with recombinant and endogenous cyclin D1 proteins through an unknown molecular basis to inhibit HepG2 cell growth and proliferation. Here, using phage display and in silico protein structure modeling methods combined with cyclin D1 mutational analysis, key residues that bind to ADκ were identified. Notably, residue K112 within the cyclin box was required for cyclin D1–ADκ binding. In order to elucidate the molecular mechanism underlying ADκ anti-tumor effects, a cyclin D1-specific nuclear localization signal-containing intrabody (NLS-ADκ) was constructed. When expressed within cells, NLS-ADκ interacted specifically with cyclin D1 to significantly inhibit cell proliferation, induce G1-phase arrest, and trigger apoptosis of MCF-7 and MDA-MB-231 breast cancer cells. Moreover, the NLS–ADκ–cyclin D1 interaction blocked binding of cyclin D1 to CDK4 and inhibited RB protein phosphorylation, resulting in altered expression of downstream cell proliferation-related target genes. We identified amino acid residues in cyclin D1 that may play key roles in the ADκ–cyclin D1 interaction. A nuclear localization antibody against cyclin D1 (NLS-ADκ) was constructed and successfully expressed in breast cancer cells. NLS-ADκ exerted tumor suppressor effects via blocking the binding of CDK4 to cyclin D1 and inhibiting phosphorylation of RB. The results presented here demonstrate anti-tumor potential of intrabody-based cyclin D1-targeted breast cancer therapy.

Expression of endoplasmic reticulum-retained anti-cyclin D1 intrabody in HeLa cells

Construction of eukaryotic expression vectors of cyclin D1 and cyclin B1 and transfection into HeLa cells

Construction of expression vector for anti-cyclin D1 intrabody AD5N and its inhibitory effects on cell proliferation of breast cancer

Expression and Identification of Human Cyclin D1 and CDK4 Proteins

A Cyclin D1-Specific Single-Chain Variable Fragment Antibody That Inhibits HepG2 Cell Growth and Proliferation.

Expression And Purification Of A Human Anti-Cyclin D1 Single-Chain Variable Fragment Antibody Ad5 And Its Characterization

Cloning and Eukaryotic Expression of Cyclin B1,D1,E1

[Expression of (His)(6)-Eif3s4 Fusion Protein in Human Breast Cancer Cell Bcap37].

[The Influence on Expression of Cyclin D1 by Anti-Sense Oligonucleotide Expression Vector].

Construction of Cyclin D1 Recombinant Plasmids and Its Expression in Human Nasopharyngeal Carcinoma Cells

Eukaryotic Expression of EGFP-Tagged Human Cell Division Cy clin 25 Homolog C and its Biological Function Detection

A Specific Anti-Cyclin D1 Intrabody Represses Breast Cancer Cell Proliferation by Interrupting the Cyclin D1–CDK4 Interaction

Soluble Expression and Purification of Recombinant Human Cyclin D1 in E.coli BL21

[Establishment of a Transgenic Cell Line with Stable Expression of Human CD14].

Successful Construction and Stable Expression of an Anti-Cd45ra Scfv–egfp Fusion Protein in Chinese Hamster Ovary Cells

A Novel Recombinant Protein Tat-Gfp-Kdel with Dual-Function of Penetrating Cell Membrane and Locating at Endoplasm Reticulum

Expression and Identification of Soluble EGF Receptor Extracellular Domain in HeLa Cells

[Construction, Identification and Expression of Recombinant Eukaryotic Vector Pegfp-Bmi-1].

Cloning of 9.1C3 Intrabody Gene and Inhibitory Function of the Intrabody on the Expression of 9.1C3 Molecule

The Establishment and Identification of the Stable Transfectant of HeLa Cell Expressing Human New Gene( PCIA1)

CONSTRUCTION AND IDENTIFICATION OF EUKARYOTIC EXPRESSION PLASMID OF CYCLIN D1